Biopharma challenges leaders want to tackle

Boosting public trust, delivering genuine breakthroughs and getting trials off the ground remain top-of-mind issues in the industry.

By Meagan Parrish • July 23, 2026

Why the FDA’s top spot could sit empty for months

Multiple factors could get in the way of confirming a new commissioner before the midterm elections, experts said, leaving the agency’s long-term initiatives in limbo.

By Susanna Vogel • July 22, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Beyond weight loss: Lilly aims for leadership in brain science

Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.

By Kelly Bilodeau • July 21, 2026

As the Ebola outbreak rages, new treatments are headed into trials. Will they work?

The strain causing the current outbreak has no approved treatments or vaccines but global organizations are rushing to change that.

By Alexandra Pecci • July 20, 2026

Long days, dinners with copious alcohol, and the hunt for emerging assets in China

Why building relationships, navigating cultural nuances and preparing for different deal structures are key to investing in China’s promising drugs.

By Meagan Parrish • July 17, 2026

Compounders maintain a firm grip on the GLP-1 market

Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

By Kelly Bilodeau • July 17, 2026

Biotech funding gap widens despite rebound in VC investment

Nearly 70 venture-backed biotech startups raised more than $9.1 billion between January and June, but the majority already had drugs in testing.

By Gwendolyn Wu • July 14, 2026

What policies could last — or could get axed — amid leadership churn at FDA

How new review policies, the use of AI and other recent FDA changes are being impacted by high turnover at the top.

By Kelly Bilodeau • July 10, 2026

What pharma leaders wish they knew on day 1

PharmaVoice checked in with four life sciences executives after they landed a new role. Now they’re looking back on what they learned.

By Alexandra Pecci • July 9, 2026

HHS plan to speed drug R&D won’t remove ‘self-inflicted’ delays

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

By Kelly Bilodeau • July 8, 2026

Can anyone catch up to Eli Lilly?

While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.

By Kelly Bilodeau • July 7, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

Can pharma sustain its $2T trajectory?

GLP-1s will fuel the industry’s growth in the coming years if outside forces don’t get in the way.

By Kelly Bilodeau • July 2, 2026

Doctor-turned-dealmaker reveals his M&A playbook

Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.

By Kelly Bilodeau • July 1, 2026

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.

By Kelly Bilodeau • June 30, 2026

3 late-stage MASH drugs that could rival Rezdiffra

The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.

By Alexandra Pecci • June 29, 2026

BIO 2026: Where pharma leaders say AI hasn’t delivered

AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype.

By Meagan Parrish • June 26, 2026

A ‘nightmare bacteria’ is surging while investment in antibiotics lags

Experts are sounding the alarm about the rise in drug-resistant superbugs and urging more action.

By Kelly Bilodeau • June 25, 2026

Recent pharma exec shake-ups signal strategic shifts

Whether from layoffs or exits, Novo Nordisk, Genentech and Allogene saw changes to their executive teams over the past few months.

By Kelly Bilodeau • June 24, 2026

Pfizer CFO departs for consumer goods sector

Dave Denton joined Pfizer in 2022 from Lowe’s Companies and is leaving for an unspecified “professional opportunity” in consumer goods, the company said.

By Maura Webber Sadovi • Updated June 18, 2026

As M&A rebounds, here’s how pharmas can prepare to seal a deal

Drugmakers that aren’t ready when financial opportunity knocks could get caught flat-footed in a competitive market.

By Kelly Bilodeau • June 18, 2026

Why ivermectin is in the limelight again

As patient interest rises for using the antiparasitic drug in cancer, it's having an impact on R&D in the space.

By Kelly Bilodeau • June 17, 2026

How Lilly is defending its GLP empire

Eli Lilly's recent GLP-2 deal with Hanmi Pharm is another step in the drugmaker’s quest to grow its GLP franchise beyond weight loss and deepen its push into gastrointestinal disease.

By Alivia Kaylor • June 16, 2026

The biotech market is rebounding. So where are the executive jobs?

The industry is showing favorable economic signs, but biotech companies are still taking a measured approach to hiring leaders.

By Kelly Bilodeau • June 15, 2026

Astellas taps AI to reshape clinical programs as rising stars emerge

As it prepares to compete in the KRAS arena, the Japanese pharma has retooled its approach to clinical development.

By Meagan Parrish • June 12, 2026